A recent Brazilian study published in Nature Cardiovascular Research has highlighted promising pathways for preventing and ...

Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).

A recent study found that combined tocilizumab and glucocorticoid therapy for at least 6 months did not fully eliminate ...

Mitochondria, often seen as cellular powerhouses, play a surprising role in immune regulation. Researchers found that ...

This research team evaluated the effectiveness of switching patients to faricimab treatment by assessing their outcomes after ...

A recent trial showed that nicotinamide riboside supplementation might reduce airway inflammation in patients with COPD who ...

Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding ...

Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system—a group of proteins that ...

Researchers discovered a previously unknown mechanism that may drive tissue damage and a new target for drug discovery.

“In addition to decreasing the inflammation by decreasing lesional staphylococcus aureus, the mupirocin treatment also lowered skin monocyte levels, which are important in driving cutaneous lupus,” ...

These suggest the potential of a repurposed marketed drug to modulate inflammation through a newly ... has prompted growth in the allergy treatment market, which Imarc Group projects will expand ...

Medically reviewed by Qin Rao, MD Pill esophagitis, or drug-induced esophagitis, occurs when oral medications cause ...